Regular physical activity prevents the development of chronic muscle pain through the modulation of central mechanisms that involve rostral ventromedial medulla (RVM). We tested if pharmacological blockade or genetic deletion of mu-opioid receptors in physically active mice modulates excitatory and inhibitory systems in the RVM in an activity-induced hyperalgesia model. We examined response frequency to mechanical stimulation of the paw, muscle withdrawal thresholds, and expression of phosphorylation of the NR1 subunit of the N-methyl-D-aspartate receptor (p-NR1) and serotonin transporter (SERT) in the RVM. Mice that had performed 5 days of voluntary wheel running prior to the induction of the model were compared with sedentary mice. Sedentary mice showed significant increases in mechanical paw withdrawal frequency and a reduction in muscle withdrawal threshold; wheel running prevented the increase in paw withdrawal frequency. Naloxone-treated and MOR 2/2 mice had increases in withdrawal frequency that were significantly greater than that in physically active control mice and similar to sedentary mice. Immunohistochemistry in the RVM showed increases in p-NR1 and SERT expression in sedentary mice 24 hours after the induction of the model. Wheel running prevented the increase in SERT, but not p-NR1. Physically active, naloxone-treated, and MOR 2/2 mice showed significant increases in SERT immunoreactivity when compared with wild-type physically active control mice. Blockade of SERT in the RVM in sedentary mice reversed the activity-induced hyperalgesia of the paw and muscle. These results suggest that analgesia induced by 5 days of wheel running is mediated by mu-opioid receptors through the modulation of SERT, but not p-NR1, in RVM.
Introduction
While exercise is an important component in managing musculoskeletal pain conditions, 5, 9, 22, 52 it can enhance pain and hyperalgesia in chronic musculoskeletal pain conditions in humans and animals. 14, 54, 56, 58 An acute bout of exercise enhances hyperalgesia in sedentary mice, while regular physical activity prevents the development of hyperalgesia. 48, 55 Hyperalgesia of the muscle, primary hyperalgesia, requires 8 weeks of physical activity to prevent its development, but both 5 days and 8 weeks of physical activity prevent the development of hyperalgesia of the paw, secondary hyperalgesia. 4, 48, 55 These data suggest that 5 days of physical activity produces its effects primarily through modulation of central nervous system pathways. However, the mechanisms for how short-duration physical activity prevents hyperalgesia are unknown.
The nucleus raphe magnus (NRM), nucleus raphe obscurus (NRO), and nucleus raphe pallidus (NRP), part of the rostral ventromedial medulla (RVM), not only inhibit and facilitate nociceptive behaviors but also modulate motor responses 11, 19, 42, 65 and thus may be involved in modulating effects of activity on nociception. In the NRM, NRP, and NRO, we previously showed increased phosphorylation of the NR1 subunit of the N-methyl-D-aspartate (NMDA) receptor (p-NR1) in models of muscle pain, neuron activation by an acute bout of exercise, and increases in the serotonin transporter (SERT) in a neuropathic pain model 6, 12, 56 ; the increases in p-NR1 and the increase in SERT are reduced by physical activity or exercise. 6, 55 In nerveinjured rats that performed treadmill running, there is an increase in met-enkephalin in the RVM, and supraspinal blockade (intracerebroventricular) of opioid receptors or depletion of serotonin prevents analgesia. 4, 6, 57 Together these studies suggest that both opioids and serotonin mediate exercise-induced analgesia. However, it is unknown if there are alterations in SERT in models of muscle pain, if increases in SERT mediate hyperalgesia, or if there are interactions between opioid and serotonin systems in activity-induced analgesia.
Classical pharmacological studies show that the RVM uses opioids to produce analgesia, and this opioid-induced analgesia is in part mediated by serotonin. 1, 28, 42 Serotonergic neurons receive input from endogenous opioid peptides, and both coexist in RVM neurons. 3, 21 Furthermore, systemic depletion of Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.
serotonin, or blockade of serotonin receptors in the RVM, prevents the analgesic effects of morphine delivered systemically or into the RVM. 8, 49 These data provide anatomical and pharmacological evidence for an interaction between opioidergic and serotoninergic systems in the RVM. On the other hand, increased facilitation in the RVM modulates secondary hyperalgesia 41, 42, 60, 63 and ON-cells, facilitatory RVM neurons, express mu-opioid receptors (MOR). 41, 42 Also, NMDA receptors play a key role in facilitation from the RVM as blockade of NMDA receptors reduces muscle hyperalgesia, downregulation of NR1 reduces muscle hyperalgesia, and there is increased p-NR1 in models of muscle pain. [10] [11] [12] Thus, we propose that activityinduced hyperalgesia and activity-induced analgesia modulate SERT and p-NR1 in the RVM through mu-opioid receptors.
The current study tested if p-NR1 and SERT expression increased in the RVM in a chronic muscle pain model, if blockade of SERT in the RVM reversed the hyperalgesia, and if shortduration physical activity activated mu-opioid receptors to prevent the development of analgesia and reductions in p-NR1 and SERT in the RVM.
Methods

Animals
All experiments were approved by the Animal Care and Use Committee at the University of Iowa and are in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Adult, male and female, physically active and sedentary C57BL/6j (wild-type [WT]) and mu-opioid receptor knockout (MOR 2/2 ) mice were used (Jackson Laboratories, Bar Harbor, ME). Animals were housed in the animal care unit of the University of Iowa, in a 12-hour dark/light cycle, with all tests performed during the light cycle. Food and water were available to the animals ad libitum.
Activity-induced pain model
For the activity-induced pain model, mice were briefly anesthetized with isoflurane (3%). Then, a sterile saline (20 mL) solution of pH 5.0 was injected into the left gastrocnemius muscle. Five days later, mice performed a bout of 2 hours of running wheel exercise followed by a second injection of saline of pH 5.0, as previously published. 64 This model produces muscle fatigue, a reduction in withdrawal thresholds of the muscle (ie, primary hyperalgesia), and increased response frequency to mechanical stimulation of the paw (ie, secondary hyperalgesia). 54, 64 It is generally thought that secondary hyperalgesia reflects changes in the central nervous system, while primary hyperalgesia reflects changes in the peripheral nervous system. 16, 23 Two injections of saline of pH 5.0 alone or the 2-hour exercise task alone does not produce tissue damage and does not result in hyperalgesia. 64 
Short-duration physical activity
Physically active mice had free access to running wheels in their home cages for 5 consecutive days to promote a short-duration regular physical activity based on voluntary exercise without the influence of a training effect. This protocol prevents the development of hyperalgesia at the paw (secondary hyperalgesia) in chronic muscle pain models. 48, 55 Sedentary control mice were maintained in their regular housing without running wheels. Both physically active and sedentary mice were housed individually for the same 5-day period. Running wheels were removed from the cages prior to the induction of the model.
Behavioral testing
Mice were acclimated to the behavioral tests 2 times per day for 2 days. Mice were placed in small clear cubicles on an elevated wire mesh table for 20 minutes to be acclimated to the testing for paw withdrawal frequency with von Frey filaments (North Coast Medical, Gilroy, CA). Mice were placed in a glove for 5 minutes to acclimate to the muscle withdrawal thresholds test with tweezers. The investigator performing the tests was blinded to group allocation. Two tests were chosen to examine nociceptive behaviors in mice based on prior studies. The paw withdrawal frequency to noxious mechanical stimuli was used to examine a site outside the site of insult as a measure of secondary hyperalgesia. The muscle withdrawal threshold was used to examine the site of insult as a measure of primary hyperalgesia. The activity-induced hyperalgesia model induces an increased paw withdrawal frequency to mechanical stimulation and a decrease in withdrawal threshold of the muscle. 48, 54, 64 Five days of physical activity reduces the increased withdrawal frequency of the paw but not the withdrawal threshold of the muscle. 48 These two measures likely reflect different underlying mechanisms.
Paw withdrawal frequency
To assess the effect of exercise on secondary hyperalgesia, paw withdrawal to mechanical stimulation was tested ipsilaterally as previously described. 35 A 0.4-mN von Frey filament was applied to the hind paws 5 times, and the number of withdrawals was assessed; this was repeated 10 times and averaged. Data are presented as the number of responses (withdrawals ranging from 0 to 5). An increased number of responses are interpreted as cutaneous secondary hyperalgesia.
Muscle withdrawal threshold
To assess the effect of exercise on primary hyperalgesia, muscle withdrawal thresholds were measured. A pair of calibrated forceps was applied to the gastrocnemius muscle until the minimum pressure required for the animal to withdraw from the stimulus was reached. Three trials on each side were performed at each testing period and averaged. 35, 51 Data are presented as force (in milliNewtons [mN] ) and defined as the muscle withdrawal threshold. A decrease in withdrawal threshold was interpreted as primary muscle hyperalgesia. After the running wheel and behavioral assessments, animals were deeply anesthetized with sodium pentobarbital (100 mg/kg) and transcardially perfused with heparinized saline followed by 4% paraformaldehyde. Their brainstems were removed and placed in 30% sucrose overnight and then blocked and frozen in cryomolds embedded in optimal cutting temperature compound (Tissue-Tek; Fisher Scientific, Waltham, MA). Tissue sections were cut on a cryostat at 20 mm and placed on slides.
Immunohistochemistry for p-NR1 expression
All sections were immunohistochemically stained simultaneously for p-NR1 using standard immunofluorescent techniques as previously described. 54 On day 1, sections were washed with background buster and blocked with 5% normal goat serum and then incubated overnight with a primary antibody to p-NR1 Areas for counting were selected using the "specify" function of Image J software to provide the same area for each section counted as follows: NRO: width, 420, height, 876, total area, 367,920; NRM: width, 1030, height, 1004, total area, 1,034,120. For the NRP, counting area was specified manually according to the NRP's area size in each bregma coordinate and ranged from 300,000 to 600,000. The sum of the counting from 5 pictures was considered for analysis. The investigator was blinded to group during staining, picture acquisition, and counting.
Immunohistochemistry for SERT expression
All sections were immunohistochemically stained simultaneously for SERT using standard protocols. 6 Sections were blocked with 3% normal goat serum followed by a standard avidin and biotin blocking protocol (Vector Laboratories, Burlingame, CA). Sections were then incubated overnight with the primary antibody to SERT (rabbit anti-5-HT transporter, 1:500; ImmunoStar, Hudson, WI). On the second day, sections were incubated in the secondary antibody (biotinylated goat antirabbit IgG, 1:1000, 1 hour; Invitrogen, Thermo Fisher Scientific) followed by streptavidin Alexa Fluor 568 conjugate (1:1000; Life Technologies) for 1 hour. All antibodies and streptavidin were diluted in 1% normal goat serum with 0.05% Triton-X 100 in 13 phosphate-buffered saline. Slides were cover slipped with Vectashield (Vector Laboratories). We performed 2 separate experiments to test the selectivity of the SERT antibody. First, removal of the primary antibody from the protocol eliminated the SERT immunoreactivity. Second, immunohistochemical staining in tissue from SERT 2/2 mice (Jackson Laboratories) showed a loss of immunoreactivity to the antibody.
Five sections of the NRO, NRM, and NRP were digitally imaged and stored for later analysis. Areas were determined as in the p-NR1 analysis. For SERT expression quantification, the density of immunoreactivity was measured using ImageJ 1.24 software (National Institutes of Health). Specifically, each picture was first converted to 8-bit gray scale and then calibrated independently using the "uncalibrated OD" function with pixel values ranging from 0 to 255. Density values represent pixels per area and are expressed as arbitrary units. The average of density values from 5 pictures was considered for analysis. The investigator was blinded to group during staining, picture acquisition, and counting.
Experimental groups
Physically active (n 5 5-12, 2-6 males and 3-7 females) WT C57BL/6j mice were compared with sedentary (n 5 8, 4-5 males and 3-4 females) mice to show the effects of the 5-day wheel running protocol on the activity-induced pain model on behavioral and immunohistochemical analyses. Two additional experiments were performed to assess the involvement of the opioidergic system in such effects.
Experiment 1
Experiment 1 assessed if systemic blockade of mu-opioid receptors would prevent the analgesia and reduction in RVM expression of p-NR1 and SERT produced by wheel running in the activity-induced hyperalgesia model. Physically active mice were treated with systemic naloxone for 5 days during wheel running (n 5 7-8, 4 males, 3-4 females) and compared with physically active vehicle-treated control mice (n 5 6-8, 3-4 males, 3-4 females). Osmotic minipumps (3 mg·kg 21 ·d 21 naloxone; Alzet Osmotic Pumps, Cupertino, CA) were used to deliver naloxone or vehicle continuously over the 5-day wheel running period. The day before wheel running started, mice were anesthetized with isoflurane, and the osmotic minipumps were subcutaneously implanted in the area between their shoulder blades. Minipumps were removed after 5 days of wheel running and before the first injection of saline of pH 5.0.
Experiment 2
Experiment 2 investigated if genetic deletion of mu-opioid receptors would block the analgesic effect of short-duration physical activity and the reduction in RVM expression of p-NR1 and SERT produced by wheel running in the activity-induced hyperalgesia model. Both physically active (n 5 5-12, 3-7 males, 2-5 females) and sedentary (n 5 5-8, 3-4 males, 2-4 female) MOR 2/2 were compared with the physically active (n 5 5-12, 2-6 males, 3-7 females) and sedentary (n 5 8, 4-5 males, 3-4 females) WT groups. A group of naive mice (n 5 6, 3 males, 2-3 females) was added to compare the changes in immunohistochemistry. The number of animals per group in the immunohistochemistry experiments varied because some samples were removed due to poor perfusion or inadequate tissue quality of the stained area. The number of animals per group per measure and the number of males and females per group per measure are provided in Supplementary Table 1 (available online at http://links.lww.com/PAIN/A425).
Experiment 3
Experiment 3 was performed to investigate the role of SERT in the RVM on pain modulation. Sedentary mice had an intracerebral guide cannula stereotaxically implanted in their RVM 3 day prior to baseline behavior testing and first injection of saline of pH 5.0. The mice were anesthetized with ketamine or xylazine (17.5 or 2.5 mg/mL intraperitoneally) and positioned in a stereotaxic head holder. The skulls were exposed, and a small hole was www.painjournalonline.com 1699 drilled for the placement of guide cannula. The cannula was placed 25.6 mm caudal from the bregma (intra-aural 5 25.6 mm, mediolateral 5 0.0 mm, dorsoventral 5 25.7 mm from the surface of the skull). Cannulas were secured to the skull with dental cement. A dummy cannula (33 gauge; Plastics One, Torrington, CA) was inserted into the guide cannula to maintain its patency. On day 6, after postinduction behavioral measurements, 1 group of mice (n 5 5, 4 males and 1 female) received fluoxetine dissolved in saline with 10% 2-hydroxypropyl-B-cyclodextrin (10% HBC, 20 nmol/0.2 mL) injection through a 33-gauge injection cannula that extended 1 mm below the guide cannula tip. The injection cannula was attached to a 10-mL Hamilton syringe via a length of PE-20 tubing. A control group received vehicle consisting of saline with 10% HBC (n 5 5, 3 males and 2 females). Behavior testing was performed 15 minutes and 2 hours after fluoxetine or saline injection.
A third group of mice (n 5 3, 1 male and 2 females) had cannulas placed outside the RVM (missed sites) (intra-aural 5 25.6 mm caudal from bregma, mediolateral 5 21.0, dorsoventral 5 21.6 from the surface of the skull) to control for area specificity.
To determine cannula placement in the RVM, an equivalent volume of methylene blue dye was injected at the end of the experiment. Mice were then transcardially perfused with 4% paraformaldehyde, and their brains were removed and preserved in 30% sucrose. The brains were cross-sectioned into 30-mm sections on a cryostat and analyzed on a light microscope to check for cannula placements.
Statistical analysis
Results are presented as mean 6 SEM for each group for withdrawal thresholds of the muscle and for , mu-opioid receptor knockout; WT, wild type. Box plots represent the median with the 10th and 90th percentiles.
immunohistochemistry data. For response frequency of the paw, data are presented as the median with 25th and 75th percentiles. Normality was tested for withdrawal threshold of the muscle and immunohistochemistry data using a Shapiro-Wilk test. These data were all normally distributed. For withdrawal threshold of the muscle, a repeated-measures analysis of variance tested for differences across time and between groups. Post hoc tests were not performed, as there were no group differences. For immunohistochemistry data, a 1-way analysis of variance compared differences between groups followed by a post
Results
Behavioral testing
Sedentary WT mice (WT nonrunners) showed an increase in the number of withdrawals to noxious mechanical stimulation of the paw (secondary hyperalgesia) (P , 0.05, Mann-Whitney test) and a decrease in withdrawal thresholds of the muscle bilaterally (primary hyperalgesia) (P 5 0.0001, paired t test) 24 hours after the induction of the model. Five days of wheel running in WT mice significantly prevented the increased response frequency of the paw bilaterally (P 5 0.001) (Fig. 1A, B) but not the decrease in withdrawal threshold of the muscle ( Fig. 2A, B) , normally observed in sedentary WT mice.
Experiment 1 tested if the analgesic effects of wheel running use opioids by treating animals with systemic naloxone during wheel running. Physically active mice treated with systemic naloxone (3 mg·kg 21 ·d 21 ) showed a significantly greater number of withdrawals to noxious stimulation of the paw when compared to physically active mice treated with vehicle (P 5 0.001) (Fig. 1C,  D) . When testing if blockade of the mu-opioid receptors with naloxone modulated muscle withdrawal threshold, there was a significant effect for time (F 1,12 5 23.7; P 5 0.0001), but not for side (F 1,12 5 2.8; P 5 0.112), treatment (naloxone vs saline: F 1,12 5 0.002, P 5 0.96), or sex (F 1,12 5 0.52; P 5 0.49) (Fig. 2C, D) ; that is, there was a decrease in withdrawal threshold bilaterally 24 hours after the second injection of acidic saline in both the groups. Thus, 5 days of running wheel activity prevented the development of activity-induced hyperalgesia of the paw through the activation of opioid receptors.
Experiment 2 tested if mu-opioid receptors mediate the analgesia produced by wheel running by examining the effects in MOR 2/2 mice. Physically active MOR 2/2 mice had a significantly greater number of withdrawals when compared to physically active WT mice (P 5 0.004) and were similar to sedentary MOR 2/2 mice (P 5 0.27) and WT nonrunners (P 5 0.79) (Fig. 1E, F Fig. 2E, F ). An analysis of wheel-running activity with 8 mice (4 MOR 2/2 , 4 WT) showed that mice ran an average of 2.29 km after 5 days (range, 1.3-4.24 km). There was no significant difference in the distance ran by MOR 2/2 and WT mice. Thus, 5 days of running wheel activity prevented the development of activity-induced hyperalgesia of the paw through the activation of mu-opioid receptors. Figure 3 shows photomicrographs with representative images of p-NR1-positive cells in the NRO, NRP, and NRM. When comparing all groups, there was an overall significant difference in the number of positively stained cells of p-NR1 in the NRM (F 6,53 5 4.2; P 5 0.002), NRO (F 6,55 5 5.4; P 5 0.0001), and the NRP (F 6,50 5 4.6; P 5 0.001). We initially tested if there was an increase in p-NR1-positive cells after the induction of the activityinduced pain model and if this was modulated by wheel running. Sedentary WT mice showed a significant increase in the number of p-NR1-positive cells in NRM (P 5 0.02) and NRO (P 5 0.0001) but not in NRP (P 5 0.28) 24 hours after the induction of the model when compared to naive mice. Similarly, there was a significant increase in p-NR1-positive cells in the NRM (P 5 0.04) and NRO (P 5 0.001) in animals with 5 days of wheel running prior to the induction of the model; there were no significant differences between wheel running and sedentary animals (NRM: P 5 0.87; NRO: P 5 0.12; NRP: P 5 0.43; Fig. 4A ).
p-NR1 expression in the RVM
In experiment 1, naloxone-treated and vehicle-treated, physically active mice showed a similar number of p-NR1-positive cells in the NRM (P 5 1.0), NRO (P 5 1.0), and NRP (P 5 0.93). When compared to naive mice, vehicle-treated physically active mice showed significant increases in the number of p-NR1-positive cells in the NRM (P 5 0.001) and NRO (P 5 0.001), but not the NRP (P 5 0.06). Similarly naloxone-treated mice also showed significant increases in the number of p-NR1-positive cells in the NRM (P 5 0.002), NRO (P 5 0.001), as well as the NRP (P 5 0.004). In experiment 2, we tested if mu-opioid receptors modulated p-NR1 immunoreactivity by examining MOR 2/2 mice. Physically active MOR 2/2 mice showed significant increases in the number of p-NR1-positive cells in the NRM (P 5 0.02) and NRO (P 5 0.0001) when compared to naive mice but not when compared to physically active WT mice (NRM: P 5 0.87; NRO: P 5 0.38; Fig. 4B, C) . No sex differences were observed. Figure 5 shows photomicrographs representing SERT expression in the NRO, NRP, and NRM from all groups. The inset in the photomicrographs from naive mice shows a lack of immunoreactivity in the SERT 2/2 mice, demonstrating specificity of the antibody to SERT. When comparing all groups, there were significant overall differences in staining density for SERT in the NRM (F 6,44 5 9.5; P 5 0.0001), NRO (F 6,47 5 12.1; P 5 0.0001), and NRP (F 6,43 5 11.5; P 5 0.0001). We initially tested if there was an increase in SERT after the induction of the activityinduced pain model and if this was modulated by wheel running. Sedentary WT mice showed a significant increase in SERT density in the NRM (P 5 0.009), NRO (P 5 0.001), and NRP (P 5 0.02) 24 hours after the induction of the model when compared to naive mice. When compared to sedentary mice, the increase in SERT in the activity-induced pain model was prevented by 5 days of wheel running in the NRM (P 5 0.03) and NRP (P 5 0.006) but not in the NRO (P 5 0.09; Fig. 6A ). The staining density for SERT in the physically active WT mice was similar to that observed in naive mice (NRM: P 5 0.85; NRO: P 5 0.12; NRP: P 5 0.77).
SERT expression in the RVM
Experiment 1 tested if systemic naloxone altered p-NR1
staining when compared to vehicle controls in physically active mice. Physically active mice treated with systemic naloxone showed greater SERT immunoreactivity in the NRM (P 5 0.02), NRO (P 5 0.04), and NRP (P 5 0.02) when compared to physically active vehicle-treated mice 24 hours after the induction of the model (Fig. 6B) . Experiment 2 tested if mu-opioid receptors mediated the alterations in SERT immunoreactivity by examining MOR 2/2 mice. Physically active MOR 2/2 mice showed significant increases in SERT density in the NRM (P 5 0.002), NRO (P 5 0.004), and NRP (P 5 0.0001) when compared to physically active WT mice. However, it should be noted that in sedentary MOR 2/2 mice, there was a greater increase in SERT immunoreactivity 24 hours after the induction of the model when compared to sedentary WT mice for the NRO (P 5 0.006) and NRP (P 5 0.001) but not for the NRM (P 5 0.68; Fig. 6C ). No sex differences were observed.
Experiment 3
Since there were increases in SERT immunoreactivity in the RVM after the induction of the activity-induced pain model, we tested if blockade of SERT in the RVM would reverse the muscle and paw hyperalgesia. All groups of mice showed an increase in the paw withdrawal frequency to mechanical stimulation and a decrease in muscle withdrawal thresholds (Fig. 7) . Microinjection of fluoxetine (20 nmol/0.2 mL) into the RVM decreased the paw withdrawal frequency to mechanical stimulation (15 minutes; P 5 0.008 ipsilateral and contralateral) and increased the muscle withdrawal threshold 15 minutes (15 minutes; P 5 0.005 ipsilateral and contralateral) after the injection when compared Figure 2 . Mechanical hyperalgesia of the muscle. Graphs represent the withdrawal threshold of the muscle for the ipsilateral (A, C, and E) and contralateral (B, D, and F) sides. (A and B) After the induction of activity-induced hyperalgesia, the withdrawal threshold of the muscle decreases bilaterally in sedentary WT mice (WT nonrunners). Five days of running wheel activity had no effect on the decreased withdrawal threshold of the muscle (WT runners). *P , 0.05 when compared to baseline. (C and D) Treatment with naloxone during the 5 days of wheel running had no effect on the decreased withdrawal threshold of the muscle when compared to saline treatment. *P , 0.05 when compared to baseline (E and F). MOR 2/2 runners showed significantly greater increases in the number of responses to mechanical stimulation of the paw when compared to WT runners and MOR 2/2 nonrunners. *P , 0.05 when compared to baseline. MOR to vehicle controls. By 2 hours, the fluoxetine effects were reversed, and there was an increase in paw withdrawal frequency to mechanical stimulation and a decrease in muscle withdrawal threshold similar to that observed 24 hours after the induction of the activity-induced pain model. Mice injected with fluoxetine outside the RVM into the medial vestibular nucleus (MVe) and spinal vestibular nucleus (SpVe) (missed sites, Fig. 7) showed no change in the number of responses of the paw to mechanical stimulation (n 5 3; ipsilateral: median, 3.2; 25th percentile, 3.0; 75th percentile, 3.4; contralateral: median, 2; 25th percentile, 1.9; 75th percentile, 2.6) or the muscle (n 5 3; mean 6 SD, ipsilateral, 1188 6 91; contralateral, 1191 6 30) 15 minutes after the injection and were similar to vehicle controls. When injections were placed in the lateral paragigantocellularis or the gigantocellularis on the contralateral side, there was a significant decrease in the number of responses to mechanical stimulation of the paw 15 minutes after the injection bilaterally (n 5 5; median with 25th and 75th percentiles; ipsilateral: P 5 0.04; 1.2, 1.2-1.2; contralateral: P 5 0.02; 0.8, 0.6-1) when compared to vehicle controls. Similarly, injections into the lateral paragigantocellularis or the gigantocellularis on the contralateral side increased the withdrawal thresholds of the muscle bilaterally (n 5 5; mean 6 SD; ipsilateral, 1365 6 74; P 5 0.01; contralateral, 1330 6 62; P 5 0.02; contralateral) when compared to vehicle controls.
Discussion
The current study showed that short-duration physical activity prevented the development of secondary hyperalgesia of the paw, but not primary muscle hyperalgesia, in an activity-induced pain model that was mediated by the activation of mu-opioid receptors. We further show, in sedentary mice, there is an increase in SERT expression in the RVM, and blockade of SERT in the RVM after the induction of the activity-induced pain model reverses the hyperalgesia, showing a functional role for the increases in SERT. Regular physical activity prevents the increases in SERT expression in the RVM, and alterations in SERT by wheel running do not occur after the treatment of animals with naloxone or genetic deletion of MOR. Together, these data suggest an interaction between the serotonergic and opioidergic systems in the analgesic effects of regular physical activity. Consistent with prior studies, 48 ,55 short-duration wheel running prevents secondary, but not primary, hyperalgesia, suggesting that the analgesia involves central nervous system mechanisms. 62 On the other hand, prior studies show that 8 weeks of running wheel activity reduces both primary muscle hyperalgesia and secondary paw hyperalgesia, 48, 55 suggesting that additional mechanisms underlie the reduction in primary hyperalgesia with longer duration physical activity. In support, we show that 8 weeks of prior running wheel activity alters macrophage phenotype in the muscle and the analgesia produced is reversed by blockade of IL-10 receptors in the muscle. 35 Thus, short-duration exercise primarily has an effect on modulating central nervous system excitability and inhibition. Data from the current study show that mu-opioid receptors mediate the analgesia produced by short-duration wheel running, which is consistent with the prior work showing that systemic blockade of opioid receptors prevents exercise-induced analgesia in healthy human subjects, normal uninjured animals, and animal models of pain, and increased endogenous opioid peptides and altered MOR expression occurs in central nervous system sites including the RVM. 4, 15, 18, 20, 27, 30, 33, 38, 57 The current study also shows that short-duration running wheel activity reduces SERT expression in the RVM, which is consistent with prior studies showing that regular exercise increases 5-HT in central nervous system sites, reduces SERT in RVM, and increases 5-HT receptor expression in RVM, in normal uninjured animals and animals with nerve injury. 4, 6, 7, 17, 38, 57 Although previous studies have shown a role of opioidergic and serotoninergic systems in exercise-induced analgesia, separately, we show, for the first time, that an interaction between the 2 systems mediates the analgesia produced by regular exercise.
Two populations of neurons in the RVM, ON-cells and OFFcells, modulate nociception, with increased activation of ON-cells promoting nociception and increased activity of OFF-cells promoting analgesia. 19, 24, 26, 29, 33 MOR are expressed on ON-cells; MOR agonists directly inhibit ON-cells, and removal of ON-cells prevents secondary hyperalgesia. 41, 42 A third subset of neurons in the RVM, neutral cells, do not change their firing in response to noxious stimuli and are thought to be serotonergic. 43 Recent evidence, however, shows 5-HT connections with all cells types in the RVM with greatest number of 5-HT connections on neutral cells, slightly less on OFF-cells, and the least on ON-cells. 43 Furthermore, 5-HT and opioids coexist in RVM neurons, and opioids enhance serotonin activity in the RVM by increasing the rate of serotonin turnover. 3, 21 Our data show that the reduced SERT expression in the RVM by wheel running does not occur after the blockade of opioid receptors or in MOR 2/2 mice, suggesting that MOR activation modulates SERT expression in the RVM. MOR regulation of SERT could be a result of direct interactions between endogenous agonists and their intracellular pathways within the same cell, indirect modulation between different pain sites, or by direct gene interactions. MOR activation increases the activation of intracellular signaling pathways, such as protein kinase C, which can directly phosphorylate and downregulate SERT. 44 Alternatively, systemic morphine induces release of serotonin in the RVM, and microinjection of a mu-opioid agonist into the PAG produces analgesia through the activation of serotonin receptors in the RVM, 32, 59 showing an interaction between different analgesic pain sites. In people with fibromyalgia, exercise-induced analgesia is associated with significant gene-to-gene interactions between the mu-opioid receptor and the serotonin transporter. 61 Specifically, stronger exerciseinduced analgesia to a single isometric contraction is associated with strong opioid signaling (OPRM1-G) in combination with low expression of serotonin transporter. 61 Thus, interactions between opioid receptors and the serotonin transporter could occur through multiple different mechanisms. Future studies should determine which mechanisms contribute to the analgesic effects of exercise in animals and human subjects with pain.
Increases in SERT expression in the RVM underlie the development of activity-induced hyperalgesia
The activity-induced pain model produces widespread hyperalgesia with decreases in muscle withdrawal thresholds and increases in paw withdrawal frequency to mechanical stimulation bilaterally. These data are consistent with prior studies using this model, as well as those in other animal models of muscle pain. [54] [55] [56] These models mimic clinical conditions with chronic widespread pain, like fibromyalgia. 53 These widespread pain conditions are associated with alterations in central excitability in both animal models and human subjects with fibromyalgia, show responsiveness to centrally directed pharmaceutical agents, and are responsive to exercise (for review see Ref. 53 ). 4, 50, 55, 64 The current study shows that blockade of SERT in the RVM of sedentary mice reverses the activity-induced hyperalgesia, showing, for the first time, that alterations in the serotonin transporter, an inhibitory neurotransmitter system, plays a function role in hyperalgesia. Consistent with this hypothesis, classical pharmacological studies in uninjured animals show that microinjection of 5-HT or a SERT inhibitor into the RVM increases the tail flick latency, blockade of serotonin receptors in the RVM prevents analgesia produced by the stimulation of the PAG, systemic morphine increases 5-HT in the RVM, and application of 5-HT to RVM neurons excites 66% of RVM cells. 32, 36, 37, 59 Thus, we propose that increases in serotonin in the RVM mediate analgesia, while decreases in serotonin mediate hyperalgesia.
The current data are also consistent with human studies in people with chronic widespread pain that show clinical efficacy of nonselective reuptake inhibitors in people with chronic widespread pain, such as fibromyalgia, 53 and reduced endogenous pain inhibition, as measured by a conditioned pain modulation test. 31, 34, 53 This altered inhibition may be related to altered serotonin levels since people with fibromyalgia have reduced serum and cerebrospinal levels of serotonin, its precursor, tryptophan, and its metabolite 5-HIAA. 46 ,47 Simultaneously, there is reduced mu-opioid receptor binding in brainmodulating regions in people with fibromyalgia, despite higher cerebrospinal fluid levels of enkephalins. 2, 25 It is possible, therefore, that the loss of inhibition in those with chronic widespread pain is due to alterations in serotonin and opioid systems.
Short-duration exercise does not alter p-NR1 expression in the RVM
We hypothesized that increases in p-NR1 in the RVM, induced in chronic muscle pain models, would be reduced by short-duration physical activity through the activation of MOR in the RVM. MOR are expressed on ON cells in the RVM, and activation of MOR decreases their activity. 41, 42 In models of chronic muscle pain, in the RVM, prior studies show increases in glutamate and p-NR1 and that blockade of NMDA receptors reduces hyperalgesia and downregulation of NR1 prevents hyperalgesia, while overexpression of NR1 in uninjured animals produces mechanical hyperalgesia.
11,12,45,54, 55 The current study shows increases in p-NR1 in the RVM after the induction of activity-induced pain model, which is consistent with prior studies in chronic muscle pain models. 11, 12, 54, 55 Prior studies also show that wheel running reduced p-NR1 in both an activity-induced and a chronic muscle pain model. 55 This is in direct contrast to the current study, which shows that wheel running had no effect on the increased p-NR1 in the activity-induced pain model. The reasons for these differences are unclear but could be related to the duration of the wheel running prior to the induction of the model or the muscle insult. Our prior study showed that 5 days of wheel running prevented p-NR1 expression in the activity-induced model using the same acute bout of 2-hour running wheel activity but used a different muscle insult with a single-injection of a low dose of carrageenan (0.03%). 55 The inflammatory pain model could be easier to modulate with prior exercise than a noninflammatory pain model like the one used in the current study. In support, we previously showed that 8 weeks of wheel running was necessary to reduce hyperalgesia and p-NR1 in a noninflammatory pain model induced by repeated acidic saline injection. 55 We propose that regular physical activity activates multiple parallel mechanisms, and the activation of these mechanisms occurs in a timedependent fashion. For example, prior studies show an initial increase in MOR expression in hippocampus with short-duration exercise (7 days), which is followed by a decrease in MOR expression with longer-duration exercise (9 weeks). 15 Similarly, neurogenesis and altered synaptic plasticity in the hippocampus occur after long-duration exercise (2-6 weeks) but not after shortduration exercise (3-7 days). 39 Thus, alternate mechanisms that are activated with longer-term exercise may be necessary to modulate the p-NR1 increases in the RVM in the noninflammatory activity-induced pain model.
Conclusion
In individuals with chronic musculoskeletal pain, increased fatiguing exercise exacerbates their pain not only during the activity, but this effect can outlast the task for days. 13, 34 The current study suggests that activity-induced hyperalgesia activates multiple parallel mechanisms in the brain stem that result in increases in excitatory neurotransmitter activity (increased p-NR1) and decreased availability of inhibitory neurotransmitters (increased SERT). As little as 5 days of physical activity modulates the alterations in SERT and reduces secondary hyperalgesia through the activation of MOR. Understanding the underlying mechanisms for how exercise increases pain, as well as the mechanisms for how exercise decreases pain, could lead to new strategies to reduce the enhanced pain to unaccustomed exercise and provide a time course and scientific rationale to people with chronic pain to engage in regular physical activity.
